RNS Number : 9066F
Genedrive PLC
18 July 2019

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Ian Gilham</td></tr>
<tr><td>2.</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a.</td><td>Position/status</td><td>Non-Executive Chairman</td></tr>
<tr><td>a.</td><td>Initial notification /Amendment</td><td>Initial notification</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>genedrive plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>213800ZYODIRZ87Y4K14</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Ordinary shares of 1.5 pence each</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>19p</td><td>51,250</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information</td><td>N/A</td></tr>
</table>

	· *Aggregated volume* · *Price*	
e.	*Date of the transaction*	*2019-07-17; UTC time*
f.	*Place of the transaction*	*London Stock Exchange, AIM*

For further details please contact:

genedrive plc	+44 (0)161 989 0245
David Budd: CEO	
Matthew Fowler: CFO	
Peel Hunt LLP	+44 (0)207 418 8900
James Steel	
Oliver Jackson	
Stanford Capital Partners Limited	+44 (0)20 3815 8880
Patrick Claridge / John Howes	
Walbrook PR Ltd (Media Relations & Investor Relations)	+44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAEXXFSSNEAF